Aligos Therapeutics, Inc. (ALGS) Operating Margin
- Operating margin · 12 months: Value -2112.14%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -2112.14% | Operating income / revenue. Period ending 2026-06-30. $-78.99M ÷ $3.74M × 100 ≈ -2112.14% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -78.99M USD | Operating Income (Loss) |
| Revenue | 3.74M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 88.38M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-78.99M | $3.74M | (m) | $88.38M | (m) | -2112.14% |
| 2026-03-31 | $-95.67M | $4.71M | (m) | $78.30M | (m) | -2033.39% |
| 2025-12-31 | $-87.98M | $2.19M | (m) | $69.45M | (m) | -4024.93% |
| 2025-09-30 | $-86.73M | $2.62M | (m) | $68.45M | (m) | -3306.67% |
| 2025-06-30 | $-78.50M | $3.13M | (m) | $61.28M | (m) | -2506.51% |
| 2025-03-31 | $-86.35M | $3.23M | (m) | $68.41M | (m) | -2675.06% |
| 2024-12-31 | $-89.15M | $3.61M | (m) | $70.27M | (m) | -2468.96% |
| 2024-09-30 | $-94.59M | $3.68M | (m) | $76.50M | (m) | -2572.42% |
| 2024-06-30 | $-93.53M | $3.51M | (m) | $75.59M | (m) | -2663.10% |
| 2024-03-31 | $-86.25M | $6.75M | (m) | $71.27M | (m) | -1278.80% |
| 2023-12-31 | $-88.13M | $6.19M | (m) | $73.04M | (m) | -1423.47% |
| 2023-09-30 | $-84.81M | $5.52M | (m) | $69.88M | (m) | -1536.73% |
| 2023-06-30 | $-84.69M | $4.43M | (m) | $71.81M | (m) | -1909.99% |
| 2023-03-31 | $-85.94M | (m) | (m) | $71.54M | (m) | (m) |
| 2022-12-31 | $-97.58M | $0.00 | (m) | $85.08M | (m) | (m) |
| 2022-09-30 | $-112.85M | (m) | (m) | $94.58M | (m) | (m) |
| 2022-06-30 | $-126.97M | (m) | (m) | $104.92M | (m) | (m) |
| 2022-03-31 | $-136.14M | (m) | (m) | $112.96M | (m) | (m) |
| 2021-12-31 | $-128.32M | $0.00 | (m) | $104.15M | (m) | (m) |
| 2021-09-30 | $-124.66M | (m) | (m) | $103.64M | (m) | (m) |
| 2021-06-30 | $-113.15M | (m) | (m) | $92.83M | (m) | (m) |
| 2021-03-31 | $-104.85M | (m) | (m) | $85.46M | (m) | (m) |
| 2020-12-31 | $-97.83M | $0.00 | (m) | $79.89M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-54.04M | (m) | (m) | $44.04M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |